Studies have shown that bryostatin-1 treatment initially increased the anti-apoptotic protein Bcl-2, but after a period of treatment, it decreased Bcl-2 through the ubiquitin degradation pathway, thus inducing the apoptosis of the tumor cells. The gene discussed is BCL2; the disease is neoplasm.